Fluocinolone acetonide: Difference between revisions
m Adding "update inline" template for Cochrane reference |
Citation bot (talk | contribs) Removed parameters. | Use this bot. Report bugs. | Suggested by GoingBatty | Category:CS1 maint: PMC embargo expired | #UCB_Category 2/3 |
||
(8 intermediate revisions by 7 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Corticosteroid anti-inflammatory drug}} |
{{Short description|Corticosteroid anti-inflammatory drug}} |
||
{{Use dmy dates|date=July 2024}} |
|||
{{cs1 config |name-list-style=vanc |display-authors=6}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
Line 9: | Line 11: | ||
<!--Clinical data--> |
<!--Clinical data--> |
||
| tradename = Synalar |
| tradename = Synalar, others |
||
| Drugs.com = {{drugs.com|monograph|fluocinolone-topical}}<br />{{drugs.com|monograph|fluocinolone-acetonide-eent}} |
| Drugs.com = {{drugs.com|monograph|fluocinolone-topical}}<br />{{drugs.com|monograph|fluocinolone-acetonide-eent}} |
||
| pregnancy_AU = A |
| pregnancy_AU = A |
||
Line 60: | Line 62: | ||
}} |
}} |
||
'''Fluocinolone acetonide''' is a [[corticosteroid]] primarily used in [[dermatology]] to reduce skin inflammation and relieve itching. |
'''Fluocinolone acetonide''' is a fluorinated [[corticosteroid]] primarily used in [[dermatology]] to reduce skin inflammation and relieve itching.<ref name="AHFS" /> It is a synthetic [[hydrocortisone]] derivative. The fluorine substitution at position 9 in the steroid nucleus greatly enhances its activity. It was first synthesized in 1959 in the Research Department of Syntex Laboratories S.A. Mexico City.<ref>{{cite journal | vauthors = Mills JS, Bowers A, Djerassi C, Ringold HJ | title = Steroids CXXXVII. Synthesis of a New Class of Potent Cortical Hormones. 6α,9α-Difluoro-16α-Hydroxyprednisolone and its Acetonide | journal = Journal of the American Chemical Society | volume = 80 | pages = 3399–3404 | date = 1960 | issue = 13 | doi = 10.1021/ja01498a041 }}</ref> Preparations containing it were first marketed under the brand name '''Synalar'''. |
||
Fluocinolone acetonide was also found to strongly potentiate TGF-β-associated [[chondrogenesis]] of bone marrow mesenchymal stem/progenitor cells, by increasing the levels of collagen type II by more than 100 fold compared to the widely used dexamethasone.<ref name="pmid25753754">{{cite journal | vauthors = Hara ES, Ono M, Pham HT, Sonoyama W, Kubota S, Takigawa M, Matsumoto T, Young MF, Olsen BR, Kuboki T | display-authors = 6 | title = Fluocinolone Acetonide Is a Potent Synergistic Factor of TGF-β3-Associated Chondrogenesis of Bone Marrow-Derived Mesenchymal Stem Cells for Articular Surface Regeneration | journal = Journal of Bone and Mineral Research | volume = 30 | issue = 9 | pages = 1585–1596 | date = September 2015 | pmid = 25753754 | pmc = 5569386 | doi = 10.1002/jbmr.2502 }}</ref> |
Fluocinolone acetonide was also found to strongly potentiate TGF-β-associated [[chondrogenesis]] of bone marrow mesenchymal stem/progenitor cells, by increasing the levels of collagen type II by more than 100 fold compared to the widely used dexamethasone.<ref name="pmid25753754">{{cite journal | vauthors = Hara ES, Ono M, Pham HT, Sonoyama W, Kubota S, Takigawa M, Matsumoto T, Young MF, Olsen BR, Kuboki T | display-authors = 6 | title = Fluocinolone Acetonide Is a Potent Synergistic Factor of TGF-β3-Associated Chondrogenesis of Bone Marrow-Derived Mesenchymal Stem Cells for Articular Surface Regeneration | journal = Journal of Bone and Mineral Research | volume = 30 | issue = 9 | pages = 1585–1596 | date = September 2015 | pmid = 25753754 | pmc = 5569386 | doi = 10.1002/jbmr.2502 }}</ref> |
||
Fluocinolone acetonide [[intravitreal implants]] have been used to treat non-infectious [[uveitis]]. A systematic review could not determine with any confidence whether fluocinolone acetonide implants are superior to standard of care treatment for uveitis.<ref>{{cite journal | vauthors = Reddy A, Liu SH, Brady CJ, Sieving PC, Palestine AG | title = Corticosteroid implants for chronic non-infectious uveitis | journal = The Cochrane Database of Systematic Reviews | volume = |
Fluocinolone acetonide [[intravitreal implants]] have been used to treat non-infectious [[uveitis]]. A systematic review could not determine with any confidence whether fluocinolone acetonide implants are superior to standard of care treatment for uveitis.<ref>{{cite journal | vauthors = Reddy A, Liu SH, Brady CJ, Sieving PC, Palestine AG | title = Corticosteroid implants for chronic non-infectious uveitis | journal = The Cochrane Database of Systematic Reviews | volume = 2023 | issue = 8 | pages = CD010469 | date = August 2023 | pmid = 37642198 | pmc = 10464657 | doi = 10.1002/14651858.CD010469.pub4 }}</ref> A fluocinolone acetonide intravitreal implant with the brand name Iluvien is sold by biopharmaceutical company [[Alimera Sciences]] to treat [[diabetic macular edema]].<ref>{{cite web|url=https://www.healio.com/news/ophthalmology/20200702/realworld-study-shows-longterm-safety-efficacy-of-iluvien-in-dme |title=Real-world study shows long-term safety, efficacy of Iluvien in DME |website=Healio |date=2020-07-02 |access-date=2020-10-28}}</ref> |
||
<!-- Society and culture --> |
<!-- Society and culture --> |
||
Line 70: | Line 72: | ||
==Classification== |
==Classification== |
||
{{unreferenced section|date=July 2024}} |
|||
Fluocinolone is a group V (0.025%) or group VI (0.01%) [[Topical steroid#USA system|corticosteroid under US classification]]. |
Fluocinolone is a group V (0.025%) or group VI (0.01%) [[Topical steroid#USA system|corticosteroid under US classification]]. |
||
== |
==Brand names == |
||
Fluocinolone acetonide is available under the brand names Flucort-N, Iluvien, Synalar, Yutiq,<ref>{{cite web | title=Yutiq- fluocinolone acetonide implant | website=DailyMed | date=16 October 2023 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f270cad8-ed82-4969-b785-831a1910bfa6 | access-date=25 December 2023}}</ref> and others.<ref name="AHFS">{{cite web | title=Fluocinolone (Topical) Monograph for Professionals | website=Drugs.com | date=19 January 2024 | url=https://www.drugs.com/monograph/fluocinolone-topical.html | access-date=7 July 2024}}</ref><ref>{{cite web | title=Fluocinolone ophthalmic implant Uses, Side Effects & Warnings | website=Drugs.com | date=6 October 2023 | url=https://www.drugs.com/mtm/fluocinolone-ophthalmic-implant.html | access-date=7 July 2024}}</ref> |
|||
* [[Topical steroid]] |
|||
* [[Fluocinonide]] |
|||
* [[Ciprocinonide]] |
|||
* [[Glucocorticoid]] |
|||
== References == |
== References == |
||
{{reflist}} |
{{reflist}} |
||
== External links == |
|||
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/name/fluocinolone%20acetonide | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Fluocinolone acetonide }} |
|||
{{Glucocorticoids}} |
{{Glucocorticoids}} |
||
Line 89: | Line 86: | ||
{{Glucocorticoidics}} |
{{Glucocorticoidics}} |
||
{{Portal bar | Medicine}} |
{{Portal bar | Medicine}} |
||
{{Authority control}} |
|||
[[Category:Acetonides]] |
[[Category:Acetonides]] |
||
Line 95: | Line 93: | ||
[[Category:Diketones]] |
[[Category:Diketones]] |
||
[[Category:Diols]] |
[[Category:Diols]] |
||
[[Category: |
[[Category:Organofluorides]] |
||
[[Category:Glucocorticoids]] |
[[Category:Glucocorticoids]] |
||
[[Category:Otologicals]] |
[[Category:Otologicals]] |
||
[[Category:Substances discovered in the 1950s]] |
[[Category:Substances discovered in the 1950s]] |
||
{{cardiovascular-drug-stub}} |
{{cardiovascular-drug-stub}} |
Latest revision as of 15:00, 5 September 2024
Clinical data | |
---|---|
Trade names | Synalar, others |
AHFS/Drugs.com | Monograph Monograph |
Pregnancy category |
|
Routes of administration | Topical, ophthalmic intravitreal injection |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Metabolism | Liver, CYP3A4-mediated |
Elimination half-life | 1.3 to 1.7 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.607 |
Chemical and physical data | |
Formula | C24H30F2O6 |
Molar mass | 452.495 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Fluocinolone acetonide is a fluorinated corticosteroid primarily used in dermatology to reduce skin inflammation and relieve itching.[2] It is a synthetic hydrocortisone derivative. The fluorine substitution at position 9 in the steroid nucleus greatly enhances its activity. It was first synthesized in 1959 in the Research Department of Syntex Laboratories S.A. Mexico City.[3] Preparations containing it were first marketed under the brand name Synalar.
Fluocinolone acetonide was also found to strongly potentiate TGF-β-associated chondrogenesis of bone marrow mesenchymal stem/progenitor cells, by increasing the levels of collagen type II by more than 100 fold compared to the widely used dexamethasone.[4]
Fluocinolone acetonide intravitreal implants have been used to treat non-infectious uveitis. A systematic review could not determine with any confidence whether fluocinolone acetonide implants are superior to standard of care treatment for uveitis.[5] A fluocinolone acetonide intravitreal implant with the brand name Iluvien is sold by biopharmaceutical company Alimera Sciences to treat diabetic macular edema.[6]
It was approved for medical use in 1961.[7]
Classification
[edit]Fluocinolone is a group V (0.025%) or group VI (0.01%) corticosteroid under US classification.
Brand names
[edit]Fluocinolone acetonide is available under the brand names Flucort-N, Iluvien, Synalar, Yutiq,[8] and others.[2][9]
References
[edit]- ^ "Regulatory Decision Summary for Iluvien". Drug and Health Product Portal. Health Canada. 23 October 2014.
- ^ a b "Fluocinolone (Topical) Monograph for Professionals". Drugs.com. 19 January 2024. Retrieved 7 July 2024.
- ^ Mills JS, Bowers A, Djerassi C, Ringold HJ (1960). "Steroids CXXXVII. Synthesis of a New Class of Potent Cortical Hormones. 6α,9α-Difluoro-16α-Hydroxyprednisolone and its Acetonide". Journal of the American Chemical Society. 80 (13): 3399–3404. doi:10.1021/ja01498a041.
- ^ Hara ES, Ono M, Pham HT, Sonoyama W, Kubota S, Takigawa M, et al. (September 2015). "Fluocinolone Acetonide Is a Potent Synergistic Factor of TGF-β3-Associated Chondrogenesis of Bone Marrow-Derived Mesenchymal Stem Cells for Articular Surface Regeneration". Journal of Bone and Mineral Research. 30 (9): 1585–1596. doi:10.1002/jbmr.2502. PMC 5569386. PMID 25753754.
{{cite journal}}
: CS1 maint: overridden setting (link) - ^ Reddy A, Liu SH, Brady CJ, Sieving PC, Palestine AG (August 2023). "Corticosteroid implants for chronic non-infectious uveitis". The Cochrane Database of Systematic Reviews. 2023 (8): CD010469. doi:10.1002/14651858.CD010469.pub4. PMC 10464657. PMID 37642198.
- ^ "Real-world study shows long-term safety, efficacy of Iluvien in DME". Healio. 2 July 2020. Retrieved 28 October 2020.
- ^ Fischer J, Ganellin CR, eds. (2006). "Tables of Structural and Functional Analogues: Systemic Hormonal Preparations". Analogue-based Drug Discovery. John Wiley & Sons. p. 485. ISBN 9783527607495.
- ^ "Yutiq- fluocinolone acetonide implant". DailyMed. 16 October 2023. Retrieved 25 December 2023.
- ^ "Fluocinolone ophthalmic implant Uses, Side Effects & Warnings". Drugs.com. 6 October 2023. Retrieved 7 July 2024.